UPDATE: BioMarin (BMRN) Won't Sell Even for 25% - 30% Premium
Tweet Send to a FriendGet Alerts BMRN Hot Sheet
Up)
Trade BMRN Now!
(Updated - January 8, 2013 2:57 PM EST)
BioMarin Pharmaceutical (Nasdaq: BMRN) likes the course its on and wouldn't even consider selling itself right now. Not even for a 25 percent or 30 percent premium.
Speaking at the J.P. Morgan Healthcare Conference today, CEO Jacques Bienaime commented that that best way to prevent a takeover is to "keep the stock up and we are doing that." He noted that the company has received several indications of interest recently.
Any decision to sell the company would actually come from large shareholders, Bienaime noted, not him nor the Board.
Big pharmaceutical companies are generally looking to replace drugs which run a risk of patents expiring, doing so with drugs that cover rare diseases and fetch robust premiums. BioMarin is looking to file with the FDA for approval of GALNS in the U.S. GALNS is designed as an enzyme replacement therapy for Morquio A syndrome.
According to an encyclopaedia entry: "Morquio's syndrome is an autosomal recessive mucopolysaccharide storage disease, usually inherited. It is a rare type of birth defect with serious consequences." Chances of getting the disease are one in 200,000.
Bienaime suspects that approval for GALNS would bring about $1 billion in revs for BioMarin.
Shares are down 0.6 percent Tuesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
BioMarin Pharmaceutical (Nasdaq: BMRN) likes the course its on and wouldn't even consider selling itself right now. Not even for a 25 percent or 30 percent premium.
Speaking at the J.P. Morgan Healthcare Conference today, CEO Jacques Bienaime commented that that best way to prevent a takeover is to "keep the stock up and we are doing that." He noted that the company has received several indications of interest recently.
Any decision to sell the company would actually come from large shareholders, Bienaime noted, not him nor the Board.
Big pharmaceutical companies are generally looking to replace drugs which run a risk of patents expiring, doing so with drugs that cover rare diseases and fetch robust premiums. BioMarin is looking to file with the FDA for approval of GALNS in the U.S. GALNS is designed as an enzyme replacement therapy for Morquio A syndrome.
According to an encyclopaedia entry: "Morquio's syndrome is an autosomal recessive mucopolysaccharide storage disease, usually inherited. It is a rare type of birth defect with serious consequences." Chances of getting the disease are one in 200,000.
Bienaime suspects that approval for GALNS would bring about $1 billion in revs for BioMarin.
Shares are down 0.6 percent Tuesday.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Intuitive Surgical (ISRG) Trades Higher Amid Skeptical News Piece
- Gene Patent Limited by High Court in Mixed Ruling for Myriad (MYGN)
- Myriad (MYGN) Issues Response to Supreme Court Decision on Gene Patent
Create E-mail Alert Related Categories
FDA, Insiders' BlogRelated Entities
JPMorgan
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
